What is Leerink Partnrs’ Estimate for ABVX FY2029 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

Other research analysts have also issued reports about the stock. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ABIVAX Société Anonyme currently has an average rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Stock Performance

NASDAQ ABVX opened at $6.30 on Thursday. ABIVAX Société Anonyme has a 1-year low of $5.49 and a 1-year high of $17.02. The business has a 50 day simple moving average of $7.03 and a two-hundred day simple moving average of $9.48.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ABVX. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Point72 Asset Management L.P. grew its stake in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Walleye Capital LLC raised its holdings in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Finally, R Squared Ltd purchased a new position in ABIVAX Société Anonyme during the 4th quarter valued at $36,000. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.